HomeGreater Than Icon
Mutual FundsGreater Than Icon
Compare Mutual FundsGreater Than Icon
Nippon India Pharma Fund - Direct (G) vs SBI Innovative Opportunities Fund - Direct (G)

Nippon India Pharma Fund - Direct (G) vs SBI Innovative Opportunities Fund - Direct (G)

stock1

Nippon India Pharma Fund - Direct (G)

2.65%

stock2

SBI Innovative Opportunities Fund - Direct (G)

-3.28%

Graph not available
Graph not available

About Fund

Deutsche Bank AG

Karvy Computershare Pvt. Ltd.

Citi Bank HDFC Bank Ltd. Stock Holding Corporation of India

Computer Age Management Services Pvt. Ltd Computronics Financial Services India Ltd Datamatics Financial Software Services Ltd

Very High Risk

5000

8306.35

1.12

543.9665

January 1, 2013

1

Very High Risk

5000

4968.75

1.12

8.4647

July 29, 2024

0

14.96 %

22.52 %

2.65 %

-

-

-3.28 %

Sailesh Raj Bhan

MBA (Finance), CFA.

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Prasad Padala

B. Tech, MBA

Mr. Prasad Padala joined SBIFML in September 2017 as an Equity Research Analyst. He has an overall 15 years of experience. He worked for the past 11 years in the area of financial services and 4 years before that in the software industry. Prior to the current role as a fund manager, Prasad has worked as an equity analyst at SBIFML from September 2017 to August 2023 and an external consultant from August 2023 to February 2024 handling equity research. Prior to that, he was associated with following entities: Investec India - Equity Research (from August 2015 to August 2017) Springforth Capital - Investment Banking (from November 2014 - July 2015)

Vivek Gedda

B.Tech, M.Sc and MBA

Prior to joining SBI Mutual Fund, he has worked with HSBC Securities and Capital Markets India Ltd. and HSBC Electronic Data Processsing India Pvt. Ltd.

Get your FAQs right

When comparing Nippon India Pharma Fund - Direct (G) vs SBI Innovative Opportunities Fund - Direct (G), consider factors such as historical performance, expense ratios, investment strategy, risk level, and the fund manager's credibility. Moreover, look at asset allocation and how each fund fits your investment goals.
Yes, you can invest in both Nippon India Pharma Fund - Direct (G) and SBI Innovative Opportunities Fund - Direct (G) at the same time. This can help diversify your portfolio and balance risk, provided the fund manager's investment strategies streamline each other.
While comparing Nippon India Pharma Fund - Direct (G) and SBI Innovative Opportunities Fund - Direct (G), the portfolio turnover ratio indicates how frequently assets within the fund are bought and sold. A high turnover may lead to higher transaction costs and tax implications, while a low turnover ratio indicates a buy-and-hold strategy.
Yes, you can typically switch between Nippon India Pharma Fund - Direct (G) and SBI Innovative Opportunities Fund - Direct (G), subject to the fund's policies and any applicable fees. It is important to consider potential tax implications and the timing of your switch.
Yes, you can compare Nippon India Pharma Fund - Direct (G) and SBI Innovative Opportunities Fund - Direct (G) based on their dividend payouts. Look at dividends profit, consistency, and growth, as these factors can influence your overall return on investment.

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions